Design and Testing of an EHR-Integrated, Busulfan Pharmacokinetic Decision Support Tool for the Point-of-Care Clinician by Susan M. Abdel-Rahman et al.
ORIGINAL RESEARCH
published: 30 March 2016
doi: 10.3389/fphar.2016.00065
Frontiers in Pharmacology | www.frontiersin.org 1 March 2016 | Volume 7 | Article 65
Edited by:
Ronald James Wong,
Stanford University School of
Medicine, USA
Reviewed by:
Joseph E. Rower,
University of Utah, USA
Jonathan Palma,
Stanford University, USA
*Correspondence:
Susan M. Abdel-Rahman
srahman@cmh.edu
Specialty section:
This article was submitted to
Obstetric and Pediatric Pharmacology,
a section of the journal
Frontiers in Pharmacology
Received: 22 December 2015
Accepted: 07 March 2016
Published:
Citation:
Abdel-Rahman SM, Breitkreutz ML,
Bi C, Matzuka BJ, Dalal J, Casey KL,
Garg U, Winkle S, Leeder JS,
Breedlove J and Rivera B (2016)
Design and Testing of an
EHR-Integrated, Busulfan
Pharmacokinetic Decision Support
Tool for the Point-of-Care Clinician.
Front. Pharmacol. 7:65.
doi: 10.3389/fphar.2016.00065
Design and Testing of an
EHR-Integrated, Busulfan
Pharmacokinetic Decision Support
Tool for the Point-of-Care Clinician
Susan M. Abdel-Rahman 1, 2*, Matthew L. Breitkreutz 3, Charlie Bi 1, Brett J. Matzuka 1,
Jignesh Dalal 4, K. Leigh Casey 5, Uttam Garg 2, 6, Sara Winkle 3, J. Steven Leeder 1, 2,
JeanAnn Breedlove 3 and Brian Rivera 3
1Division of Clinical Pharmacology, Toxicology, and Therapeutic Innovation, Children’s Mercy Hospital, Kansas City, MO, USA,
2Department of Pediatrics, University of Missouri-Kansas City School of Medicine, Kansas City, MO, USA, 3Department of
Information Systems, Children’s Mercy Hospital, Kansas City, MO, USA, 4Division of Hematology/Oncology, Rainbow Babies
and Children’s Hospital, Case Western Reserve University, Cleveland, OH, USA, 5Department of Pharmacy, Children’s Mercy
Hospital, Kansas City, MO, USA, 6Department of Laboratory Medicine, Children’s Mercy Hospital, Kansas City, MO, USA
Background: Busulfan demonstrates a narrow therapeutic index for which clinicians
routinely employ therapeutic drug monitoring (TDM). However, operationalizing TDM
can be fraught with inefficiency. We developed and tested software encoding a clinical
decision support tool (DST) that is embedded into our electronic health record (EHR) and
designed to streamline the TDM process for our oncology partners.
Methods: Our development strategy was modeled based on the features associated
with successful DSTs. An initial Requirements Analysis was performed to characterize
tasks, information flow, user needs, and system requirements to enable push/pull from
the EHR. Back-end development was coded based on the algorithm usedwhenmanually
performing busulfan TDM. The code was independently validated in MATLAB using
10,000 simulated patient profiles. A 296-item heuristic checklist was used to guide
design of the front-end user interface. Content experts and end-users (n = 28) were
recruited to participate in traditional usability testing under an IRB approved protocol.
Results: Decision support software was developed to systematically walk the
point-of-care clinician through the TDM process. The system is accessed through
the EHR which transparently imports all of the requisite patient data. Data are
visually inspected and then curve fit using a model-dependent approach. Quantitative
goodness-of-fit are converted to single tachometer where “green” alerts the user that
the model is strong, “yellow” signals caution and “red” indicates that there may be
a problem with the fitting. Override features are embedded to permit application of a
model-independent approach where appropriate. Simulations are performed to target
a desired exposure or dose as entered by the clinician and the DST pushes the user
approved recommendation back into the EHR. Usability testers were highly satisfied with
our DST and quickly became proficient with the software.
Conclusions: With early and broad stake-holder engagement we developed a clinical
DST for the non-pharmacologist. This tools affords our clinicians the ability to seamlessly
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transition from patient assessment, to pharmacokinetic modeling and simulation, and
subsequent prescription order entry.
Keywords: software design, decision support, therapeutic drug monitoring, bone marrow transplant, usability
testing
INTRODUCTION
Busulfan is an antineoplastic agent commonly used as
part of chemical regimens to prepare patients for bone
marrow transplantation (BMT). It also reflects a drug with
a narrow “therapeutic window” or range of concentrations
within which the drug is both safe and effective. When
the plasma concentrations fall outside of this “window,”
patients are at risk for engraftment failure or life-threatening
hepatotoxicity. Simply following recommended busulfan
dosing guidelines does not ensure safety and efficacy for
individual patients owing to the wide degree of inter-individual
variability in busulfan disposition. To minimize patient risk
and maximize therapeutic outcomes, many clinicians rely
on therapeutic drug monitoring (TDM). In fact, TDM-
guided busulfan dosage adjustment is addressed in the
U.S. Food and Drug Administration-approved busulfan
product label [Busulfex R© (busulfan), 2007]. However,
operationalizing the TDM process can be fraught with
inefficiency.
We examined the TDM process at our institution and
discovered that much of the inefficiency we observed could be
attributed to outsourcing of the busulfan plasma concentration
analysis and the related modeling and simulation (Table 1).
Apart from the inefficiencies this introduced into care, we also
had concerns about the quality of care we were delivering. In
the pharmacokinetic reports provided by the reference lab, we
observed inaccurate assumptions being made about individual
plasma concentrations, false suppositions related to sample
timing, and the application of inappropriate mathematical
models to describe our patients’ data. The consequence was
an overestimation of the dose needed to achieve the desired
target exposure in nearly 100% of the patients we were
treating.
We were able to eliminate selected inefficiencies by
transitioning busulfan specimen analysis from the reference
lab to our internal Clinical Toxicology laboratory (Deng et al.,
2016). We also considered an automated consult to the Clinical
Pharmacology service to mitigate our mathematical concerns;
however, implementation of a consultation process would not
address efficiency issues. We recognized that providing the
point-of-care clinician with training and access to external TDM
software was infeasible. Not only would this strategy interrupt
physician workflow, these tools can be unnecessarily complex
to navigate and are rarely designed with the physician user in
mind (Barrett, 2015). Instead, we chose to develop a unique
decision support tool aimed at the clinician and embedded
in our electronic health record (EHR). This manuscript
details the development and testing of a clinical decision
support tool created at our institution for use by our BMT
colleagues.
MATERIALS AND METHODS
Design
Our development strategy was largely modeled based upon the
published features associated with successful decision support
tools (DSTs; Lobach et al., 2012). These include (1) involvement
of local users in the development, (2) integration within the
charting/order entry system, (3) availability at the time and
location of decision making, (4) avoidance of a requirement for
additional data entry, (5) provision of a recommendation as
opposed to an assessment, and (6) justification of the decisions
with evidence.
Stake-Holder Engagement
The project began with a Requirements Analysis to assure a basic
understanding of user needs and the requirements necessary
for optimal TDM execution. The existing process was analyzed
and the sequence of tasks along with information flows were
documented. High-level tasks were broken down into subtasks
and operations, and the informational sources required in each
subtask were recorded. The output of the requirements analysis
included process charts, task flow diagrams, task decomposition
tables, and use case scenarios. Understanding this workflow was
critical to inform development of the application. By engaging
physicians, nurses, pharmacists, pharmacologists, and clinical
laboratory personnel we were able to draw perspectives from the
various providers that are (or would soon be) involved in the
TDM process.
Back-End Development
The software flow and nested logic used to code the modeling
and simulation components of the software were based
on the algorithm established by the clinical pharmacologist
who manually performed the modeling and simulation after
transitioning busulfan analysis to our institutional laboratory
(Abdel-Rahman et al., 2016). We formulated our compartmental
pharmacokinetic modeling approach as a non-linear least square
problem, solved by the Levenberg-Marquardt algorithm with
initial parameters estimated by curve-stripping. A series of nested
logic functions were used to determine whether the data should
be fit to a one- or a two-compartment model. Quantitative
goodness-of-fit (GOF) criteria, traditionally used to determine
the appropriateness of a model (e.g., weighted sum of squares,
coefficients of variation the coefficients and exponents), were log-
adjusted, weighted, and combined to generate a 10-point scale
that is overlaid on a visual indicator alerting the user to the
strength of the model. The equations for a non-compartmental
model were also coded for implementation under certain criteria
and/or with end-user override of the compartmental analysis.
Ten-thousand patient profiles were simulated to test each
executable path and the output validated against the findings
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TABLE 1 | Inefficiencies in the busulfan TDM process at our institution.
Inefficiencies Details
Restricted scheduling • Owing to limited availability of RL personnel, scheduling of BMT patients was restricted to the first 4 days of the week
Time intensive preparatory activities • No less than 48 h before the TDM study, BMT staff must identify the ordering physician and the physician who will be receiving
the results, obtain hard copy signatures from both, and transmit both electronic and verbal orders to the RL
• The team must also coordinate specimen collection and non-routine shipping for the in-house lab
Redundant pre-delivery activities • Information related to dosing and specimen collection is documented in EHR and transcribed onto a separate hard copy
requisition form duplicating activities and introducing the potential for error
• Transmittal of these forms relies on the availability of a BMT team member and introduces unnecessary delays while the
responsible party is attending to other clinical duties
Inflexible PK analysis • Remote modeling and simulation requires interruption of the physician’s workflow to accommodate a verbal call from the PK
specialist
• Further, the lack of access to the modeling process limits the ability of the BMT team to refine the mathematical approach, and
affords the team no flexibility to examine alternative dosing strategies, should relevant clinical information arise after the
requisition has closed
• Finally, the need relay dosing recommendations by phone and fax does not permit seamless entry of the new orders into the EHR
BMT, bone marrow transplantation; EHR, electronic health record; PK, pharmacokinetic; RL, reference laboratory; TDM therapeutic drug monitoring.
generated by applying the same calculations in MATLAB R©. The
algorithm was initially implemented in portable standard C++
language as the computing core of the project and subsequently
converted to C# to facilitate integration with the user interface
(UI).
Front-End Design
Using the information gathered from the Requirements Analysis,
a wireframe prototype of the application to test the DST’s
functionality was developed in Visual Studio. A web-design
expert wrote the necessary code to integrate the back-end
code with the front-end UI and designed the UI for optimal
functionality on both desktop and portable devices using Chrome
and Internet Explorer browsers. Javascript and Javascript
libraries such as jQuery, jQueryUI, JSON, and the Highcharts
visualization package were used heavily in the development of
the UI to achieve a consistent experience across devices and
web browsers. A 296-item heuristic checklist was used to guide
design of the front-end UI (Weiss, 1993). Major areas of focus
included: Visibility of System Status, Match Between System and
the Real World, User Control and Freedom, Consistency and
Standards, Error Recognition/Prevention/Recovery, Flexibility
and Minimalist Design, Aesthetic and Minimalist Design, Help
and Documentation, Interaction with the User, and Privacy. The
UI was iteratively refined after usability testing.
Integration with the EHR
To maximize design flexibility and minimize restricting our
application to a single EHR system, we elected to integrate
our software as link within the EHR (currently operating
using Cerner R©). We developed a PowerForm that centralizes
the multidisciplinary activities associated with busulfan TDM.
Ordering a busulfan TDM study prompts a “face up” view of
the PowerForm that generates all tasks and queries related to the
study. A static order set generates labels for specimen collection.
Data holding spots were created for entry by pharmacy (dosing
weight, study dose number, total number of doses) and nursing
(infusion start/stop times, sampling times, catheters accessed for
dosing and sampling). Indicators signal the completion of all
necessary tasks. The PowerForm serves to facilitate coordination
of the TDM study and eliminates duplicative data capture.
Preparatory and pre-delivery activities were streamlined and
the steps where transcription errors could be introduced were
eliminated addressing additional inefficiencies enumerated in
Table 1.
Clicking on the software link within the PowerForm
transparently pulls in all of the relevant patient data from
the PowerForm, along with demographic data, clinical
laboratory data, and dosing information from the medication
administration record. Accessing the software outside of the
EHR requires provision of a medical record number which then
permits import of the same data described above. The software
was also built with a manual entry feature to accommodate the
analysis of data from patients that are not contained within our
institution’s EHR. Completion of the modeling and simulation
within the DST pushes a time/date stamped report back into the
EHR while completion of more than one report for the same
child prompts a warning indicating that a report has already been
submitted for that child. We elected not to integrate software
recommendations with computerized physician order entry
(CPOE) until the software has been prospectively validated.
Usability Testing
Structured cognitive walkthroughs (CW) were conducted with
individuals representing medicine, pharmacy, pharmacology,
and nursing to identify whether the interface supported the
prospective users’ needs (Polson et al., 1992). Recommendations
arising from the CW were incorporated into the application’s
design. Subsequently, 14 content experts (CE) and 14 end-
users (EU) participated in traditional usability testing to assess
efficiency, ease-of-use, and user satisfaction with the application
among a representative user populations (Table 2). Content
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TABLE 2 | Characteristics of participants in the usability testing.
Characteristic Group Content experts (n = 14) End users (n = 14)
Gender Male:Female 6:8 3:11
Age group (year) 26–39:40–59 8:6 11:3
Race Afr. American:Asian:Caucasian 2:2:10 0:2:12
Current role Resident/Fellow 1 0
Physician 11 3
Pharmacist 1 7
Pharmacologist 1 0
Nurse 0 2
Administrator 0 2
Years in current role <5:5–10:10–15:15± years 5:4:1:4 7:7:0:0
activities performed on the computer aside
from email
median (range) 5 (2–6) 5 (3–7)
Hours per week spent on a computer 5–15:15–25:26± 1:3:10 0:3:11
Computer platform most often used Mac:Windows:Both 0:12:2 4:6:4
Different browsers used for computing IE:Chrome:Firefox:multiple 2:4:0:8 1:5:1:7
Frequency with which an EHR is accessed Daily 10 11
Weekly 2 1
Monthly 1 0
A few time a year 0 0
Never 1 2
Frequency with which a computerized clinical
decision support tool is used to assist in patient
management
Daily 0 1
Once or twice a week 3 2
About once a month 3 8
A couple of times 2 1
Never 6 2
Frequency with which TDM is used to influence
clinical decision making
Daily 0 2
Once or twice a week 3 5
About once a month 5 1
A couple of times 4 2
Never 2 4
Proficiency with pharmacokinetic calculations Strong 0 2
Moderate 10 5
Weak 3 2
Not proficient at all 1 5
Frequency with which PK calculations are
applied to patient care
Daily 0 0
Once or twice a week 0 4
About once a month 2 2
A couple of times 7 0
Never 5 8
Tool most often used for PK calculations
applied to direct patient care
Handheld calculator 3 6
Microsoft Excel 6 0
Commercially available software 0 0
N/A 5 8
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experts reflected individuals having completed formal post-
doctoral training in Pediatric Clinical Pharmacology. End-users
reflected clinicians and/or administrative staff at the hospital
that could reasonably be expected to interact with the software.
Participants were observed as they completed a series of tasks
within the application centered around four distinct clinical
scenarios. Testing incorporated a think-aloud protocol in which
participants were encouraged to verbalize what they are thinking
during testing. Audio and video of the participants’ interaction
with the DST were captured using logging software designed
for usability testing (Techsmith Morae). Additional information
was collected via questionnaire. Each usability test gathered
the following measures: demographics, time to complete tasks,
number of clicks required to complete tasks (compared to
optimal paths), task success, and user perceptions of task
ease/difficulty. Overall user satisfaction and perceived usability
was measured using version 3 of the Post-Study System Usability
Questionnaire (PSSUQ v3; Sauro and Lewis, 2012). Standard
descriptive statistics were applied to describe the usability testing
participants and the PSSUQ response data. Statistical differences
in task performance between user subpopulations were examined
by application of a two-tailed, unpaired Student’s t-test. The
significance limit accepted for all statistical analyses was α =
0.05. All participants were enrolled with informed consent under
a protocol that was reviewed and approved by the Institutional
Review Board at Children’s Mercy Hospital.
RESULTS
TheDSTwe developed systematically walks the end-user through
a series of screens that select the most robust mathematical
model around which to perform simulations that target user-
defined inputs. In total, the user can arrive at a new dose and
FIGURE 1 | (A) “Lab Results” page of the software with expanded views of the fields that allow the user to (B) view nursing notes, and (C) exclude data points.
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push the clinical decision back to EHR in four mouse clicks;
however, there are options for additional decision making at each
screen.
(1) Import Patient Data. Clinicians can access the software
within the EHR or externally on the hospital’s server.
When accessed via the patient’s medical record the user
arrives at the “Lab Results” page which permits them to
confirm the patient information and visually inspect the
data (Figure 1A). All of the relevant information needed to
perform the analyses (e.g., dose, infusion duration, sample
times, etc.) are imported transparently from the EHR. The
user can view the nursing notes on this page (Figure 1B)
and, if relevant, exclude data they believe to be erroneous
or contaminated (Figure 1C). If users access the software
external to the EHR, they arrive at a screen that allows
them to input a medical record number or select manual
entry (Figure 2A). Entering a medical record will pull up all
instances of a busulfan TDM study for that child from which
the user can select the relevant dataset (Figure 2B).
(2) Perform Curve Fitting. The only executable feature on
the “Lab Results” page is a “View Model Fit” button.
The default model is a compartmental model but the
user can override this by selecting a non-compartmental
model. The software will also transparently default to a
model-independent approach when selected criteria are
met. Executing “View Model Fit” takes the user to the
“Predictive Model” page where they will see a graphic of
FIGURE 2 | (A) “Main Menu” page visible when users access the software outside of the EHR. (B) “Search Results” page that permits users to select the TDM study
of interest.
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FIGURE 3 | “Predictive Model” page of the software on which on which the user can examine the appropriateness of the default or selected model.
the curve fit and the model-type that was fit (Figure 3).
Additional features allow the user to examine the goodness-
of-fit including concentrations predicted by the model which
lay adjacent to the actual patient values and a tachometer
which consolidates the goodness-of-fit criteria discussed
above into a single indicator (Figure 3). “Green” alerts the
user that the model is strong while “yellow” signals caution
and “red” indicates that there may be a problem with the
fitting. Users that are satisfied with the model can proceed
to simulation. If the user is dissatisfied with the model they
can go back to the “Lab Results” page, re-inspect the raw data
to determine whether selected samples need to be excluded
from the fit, and/or decide whether they should override
the default fitting strategy to perform model-independent
analyses.
(3) Perform Simulations. On the “Dose Simulation” page users
will see the patient’s clearance value and predicted exposure
levels (i.e., AUC and Cavg ss) with sustained administration
at the initial dose (Figure 4A). Users can enter the dose
number at which the regimen will be changed (Figure 4B)
and the therapeutic target around which the simulations
will be based (Figure 4C) along with the numeric value for
that target. The simulations can be repeated ad infinitum
to examine the recommended dose for different exposure
targets or the resultant exposure values if the dose were
rounded up/down.
(4) Finalize the Report. When users have decided on a
final recommended dose-exposure combination, the “View
Report” button will take them to the final “Reporting” page
where they can review the recommendation, add comments,
print the report (if desired), and push the report back into
the EHR (Figure 5). The report is displayed in, and can
be retrieved from, both the “Results Review” tab and the
“Documents” section of the EHR.
Usability testing revealed that our DST could be efficiently
navigated by our testers. Median task time across all tasks
was 9.6 s with a median 1.6 mouse clicks per task. Greater
than ninety-seven percentage of tasks were completed with no
difficulty. When selected tasks were encountered more than
once, task time significantly dropped (Table 3). On average,
EU completed tasks slightly faster than CE (14.9 vs. 18.4 s);
however, this was only significant for the tasks associated with
the second (8.3 vs. 11.5 s, p= 0.05) and third (11.6 vs. 15.3 s, p=
0.01) clinical cases presented to the testers. With respect to the
remaining background characteristics, performance metrics were
largely uniform across our population. Observable demographic
difference in performance metrics could be noted for females
who completed all assigned tasks across all four cases with fewer
number of clicks than males (79.8 vs. 96.2, p = 0.03) and for
participants 26–39 years of age who demonstrated total task times
(465 vs. 729 s, p= 0.01) and average task times (14.1 vs. 22.1 s, p=
0.01) that were shorter than participants aged 40–59 years.
On a 7-point Likert scale where 1 represents the most
favorable response and 7 the least favorable response, overall
satisfaction rated a 1.55; with scores of 1.47 for system quality,
1.81 for information quality, and 1.32 for interface quality. The
distribution of scores for each element of the PSSUQ is provided
in Figure 6.
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FIGURE 4 | (A) “Dose Simulation’ page of the software from which users can conduct simulations for target dose or exposure values. Dose change (B) and target (C)
drop down menus are detailed.
DISCUSSION
By virtue of its complexity, TDM represents a multi-disciplinary
approach to disease management. Successful application of TDM
to patient care requires (1) a comprehensive knowledge of the
patient, (2) a thorough understanding of the pharmacologic
principles that drive the relationship between dose-exposure-
response, (3) expertise in mathematical and pharmacokinetic
(PK) modeling and simulation, and (4) precise and accurately
recorded specimen collection (Durieux et al., 2008). However,
TDM-related activities can be relatively arduous and are,
therefore, commonly relegated to a PK specialist who may have
no regular involvement with the patient and their care team (i.e.,
TDM activities are external to the normal flow of care; Buclin
et al., 2012).
Attempts to integrate TDM into the clinical care work
flow have been pursued for over three decades. Countless
computer-based tools that embed various functionalities have
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FIGURE 5 | “Reporting” page of the software where end users can finalize their recommendations and push the information back to the EHR.
TABLE 3 | Time in seconds to complete selected tasks.
Task Event #1 Event #2 Event #3 Event #4
Import dataa 31.1± 15.5 15.7± 8.3 11.6±9.8 10.9± 6.8
Inspect the dataa 26.8± 18.8 11.1± 6.9 8.9±7.1 10.9± 7.2
Perform curve fittingb,c 18.5± 13.6 4.3± 4.9
w/NCA warning introduced 12.7±4.2 7.2± 6.4
Evaluate the mathematical goodness-of-fitb 14.3± 15.0 8.3± 17.5
Identify the type of model that was fitb 19.0± 16.7 3.5± 2.1
Perform simulation to achieve a specified therapeutic targetd 77.3± 135.0 27.3± 22.4 19.0±9.9
Identify the new dose 5.9± 8.7 3.3± 2.1
Examine the exposures with the modified doseb 14.7± 14.4 8.6± 5.3 11.1±7.4
Finalize the report 5.7± 4.7 6.9± 6.3 4.0±3.5
Data are represented as mean ± standard deviation. NCA, non-compartmental analysis.
aEvents #2, #3, and #4 significantly faster than event #1 (p < 0.01).
bEvent #2 significantly faster than event #1 (p < 0.01).
cEvent #4 significantly faster than event #3 (p < 0.01).
dEvents #2 and #3 significantly faster than event #1 (p < 0.05).
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FIGURE 6 | Histogram of PSSUQ responses provided by our usability testers.
been developed (Sheiner et al., 1972; Proost and Meijer, 1992;
Buffington et al., 1993; Lacarelle et al., 1994). The vast majority
exist on standalone computer systems and only a few were
designed to interface with the electronic health record (Nieuwlaat
et al., 2011; Fuchs et al., 2013). Though the intended target user
for many of these systems has been the physician, less than half
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underwent any pilot testing and for those systems where studies
were undertaken, performance was evaluated in the hands of a
PK specialist rather than the non-specialized end user (Nieuwlaat
et al., 2011). Independent evaluations looking at the usefulness
and usability of these computerized tools have also engaged
pharmacists and clinical pharmacologists who already possess
expertise in TDM (Fuchs et al., 2013). Importantly, essentially
none of these tools have experienced distribution beyond the
academic center at which the software was developed. As a
result, many of these systems have failed to reach a broader
audience and, thus, have failed to demonstrate improvements in
the process of care or in patient outcomes (Nieuwlaat et al., 2011).
We designed a software tool that integrates the
multidisciplinary activities involved with busulfan TDM in an
attempt to enhance process efficiency and improve satisfaction
of our BMT team with TDM-driven busulfan dosing decisions.
The tool we developed differs markedly from the evolution
of nearly all hospital-based TDM services where Pharmacy or
Clinical Pharmacology is consulted and queued into the patient
care process. We have no knowledge of institutions wherein the
modeling tool we describe has been successfully placed into the
hands of the provider. In fact, the reverse is often seen wherein
the modeling and simulation process is presented as a “black
box” to protect the professional activities and billable domain
of the pharmacokientic specialist (Neely and Jelliffe, 2008).
However, a focus on reimbursement for a singular department
fails to consider the overall cost savings that may be appreciated
when the efficiency of the entire system is improved.
The novel DST that we developed affords providers far more
flexibility when it comes to caring for patients that require TDM-
guided dose optimization than traditional TDM practice models.
The software can be accessed 24 h a day, 7 days a week from any
computer with access to the EHR. This feature lifts restrictions as
to when the TDM studies can be performed and enables clinicians
to repeat simulations at any time during the patient’s course of
therapy. Since the user never leaves the EHR, the transition from
dose simulation to order entry is seamless. This approach nests
numerous features associated with successful DSTs, (Lobach
et al., 2012) and addresses several of the inefficiencies enumerated
in Table 1. Importantly, Clinical Pharmacologists familiar with
pharmacokinetic modeling and simulation remain accessible to
the BMT team by pager; however, the clinical team members
for whom the patient is their primary responsibility are now the
drivers of the TDM activities.
The effective TDM-based DST should be designed and vetted
by a multi-disciplinary team to ensure that it performs optimally
and supports the needs of the end-users. It should also integrate
directly into the EHR and intelligently filter, organize, and deliver
user-specific information at appropriate times to maximize the
efficiency and quality of care that the patient receives (Fuchs
et al., 2013). Both of these criteria were met in the design
and development of our DST as evidenced by the objective
performance metrics and subjective scores assigned by our
testers. As expected, testing in a broad range of users revealed
several changes that our users would like to see integrated into
the tool and the software is currently being revised to incorporate
these recommendations. A possible limitation of our testing is
that the EU comments were generated from BMT teammembers
working together at a single institution who may share a similar
understanding of TDM. Soliciting additional feedback from a
broader test audience outside of our institution may reveal
additional elements of the DST that require modification.
Immediate next-steps relate to quality assurance and
involve prospectively examining the accuracy and predictive
performance of the DST’s back-end processing algorithm.
Notably, very few investigations to date have examined whether
the standard-of-care predictions as performed in clinical
reference laboratories are corroborated by observed busulfan
levels after dose adjustment. In addition, we would like to
evaluate whether the steady-state busulfan concentrations
predicted by the DST software are corroborated by the actual
concentrations observed in BMT patients. These activities will
expose whether the back-end model can be augmented by the
inclusion of (as of yet undescribed) patient-specific factors that
may influence the accumulation of busulfan at steady-state.
Additional future considerations include deployment of the tool
beyond our institution. Our decision to build a DST that can
integrate into commercially available EHR software was driven
by the goal of making the tool accessible beyond our institution.
Deployment with partnering hospitals is in discussion and will
be considered after a satisfactory period of quality assurance and
receipt of the necessary regulatory approvals.
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